Investors who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
On January 30, 2018, post-market, Bellicum Pharmaceuticals Inc announced “that the Company has received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501”, Bellicum Pharmaceuticals Inc’s lead product candidate, “have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.” Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) declined to as low as $5.42 per share on February 6, 2018.
According to the complaint the plaintiff alleges on behalf of purchasers of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) common shares between May 8, 2017, and January 30, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 8, 2017, and January 30, 2018, the Defendants made false and/or misleading statements and/or failed to disclose that a substantial undisclosed risk of encephalopathy was associated with the Company’s lead product candidate BPX-501, and that as a result of the foregoing, Bellicum’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego